Collado Maria Victoria, Dorado Enrique, Rausch Silvia, Gomez Graciela, Khoury Marina, Zazzetti Federico, Gargiulo María, Suarez Lorena, Chaparro Rafael, Paira Sergio, Galvan Laura, Juarez Vicente, Pisoni Cecilia, Garcia Mercedes, Martinez Liliana, Alvarez Analia, Alvarez Clarisa, Barreira Juan, Sarano Judith
From the Instituto de InvestigacionesMédicas Alfredo Lanari, Caba, Argentina.
J Clin Rheumatol. 2016 Sep;22(6):299-306. doi: 10.1097/RHU.0000000000000395.
There is controversy in medical literature over the outcome of patients with lupus nephritis (LN) class II. The aim of this study was to explore the risk of histological transformation (HT) and possible factors related to negative response to treatment in patients with mesangial LN class II.
A retrospective and multicenter study was carried out that includes patients who had received a diagnosis of LN class II on their first renal biopsy. Creatinine, urine sediment, and proteinuria were recorded at the time of the first biopsy, 6 months, and 1, 2, and 5 years after the first biopsy. Response to treatment, HT, and long-term outcome were evaluated.
Forty-one patients were included. The manifestation at first biopsy was proteinuria greater than 0.5 g/d in 28 patients (68.29%; 8 [28.57%] of 28 patients had nephrotic syndrome), hematuria in 18 patients (43.90%), and deterioration of renal function in 3 patients (7.31%). During the follow-up (median, 8 years; range, 1-35 years), a new biopsy was performed in 18 patients (43.90%), and in 17 patients (17/18 [94.44%]), there was HT. Median time at rebiopsy was 32 months (range, 11-305 months). Of the 18 patients who had a second biopsy, 10 (55.55%) were on hydroxychloroquine versus 100% (19/19) of patients who did not undergo the procedure (P = 0.001). A year after the first renal biopsy, there are data available from 34 patients; of them, 24 patients (70.58%) had achieved response, and 10 patients (29.41%) had no response (NR) (missing data in 7). A higher 24-hour urinary protein at 6 months was predictor of worse outcome at 1 year, with statistical significance difference for the nonresponder group (median proteinuria, 2.3 g/d [range, 0-4.7 g/d]) compared with responders (median proteinuria, 0.28 g/d [range, 0-1.7 g/d]) (P = 0.0133).In the long-term follow-up (5 years), HT was the main cause of unfavorable outcome and was measured in 78.57% of patients (11/14 patients).
This series shows a high rate of HT in long-term follow-up. Proteinuria at 6 months made it possible to set aside patients who will have an unfavorable outcome in the long term and who will thus benefit from a more aggressive treatment. The results suggest that hydroxychloroquine had a nephroprotective effect.
医学文献中关于II类狼疮性肾炎(LN)患者的预后存在争议。本研究的目的是探讨II类系膜LN患者组织学转化(HT)的风险以及与治疗无反应相关的可能因素。
进行了一项回顾性多中心研究,纳入首次肾活检确诊为II类LN的患者。在首次活检时、6个月时以及首次活检后1年、2年和5年记录肌酐、尿沉渣和蛋白尿。评估治疗反应、HT和长期预后。
纳入41例患者。首次活检时的表现为28例患者蛋白尿大于0.5g/d(68.29%;28例患者中有8例[28.57%]患有肾病综合征),18例患者有血尿(43.90%),3例患者肾功能恶化(7.31%)。在随访期间(中位时间8年;范围1 - 35年),18例患者(43.90%)进行了再次活检,其中17例患者(17/18[94.44%])发生了HT。再次活检的中位时间为32个月(范围11 - 305个月)。在进行第二次活检的18例患者中,10例(55.55%)服用羟氯喹,而未进行再次活检的患者中100%(19/19)服用(P = 0.001)。首次肾活检1年后,有34例患者的数据;其中,24例患者(70.58%)取得了反应,10例患者(29.41%)无反应(NR)(7例数据缺失)。6个月时24小时尿蛋白较高是1年时预后较差的预测因素,无反应组(中位蛋白尿2.3g/d[范围0 - 4.7g/d])与反应组(中位蛋白尿0.28g/d[范围0 - 1.7g/d])相比有统计学显著差异(P = 0.0133)。在长期随访(5年)中,HT是不良预后的主要原因,78.57%的患者(11/14例患者)检测到HT。
本系列研究显示长期随访中HT发生率较高。6个月时的蛋白尿有助于筛选出长期预后不良、从而将从更积极治疗中获益的患者。结果表明羟氯喹具有肾脏保护作用。